Pharmaceutical - Antibiotics and Infectious diseases, Asia-Pacific

Filter

Popular Filters

Leading Chinese hepatitis B vaccine makers stop production; Pfizer drug import halted

03-01-2014

China’s Food and Drug Administration announced on January 2 that the country’s three leading manufacturers…

Anti-viralsAntibiotics and Infectious diseasesAsia-PacificBioKangtaiChinaFluconazolePfizerPharmaceuticalRegulationVaccines

MRCF invests in Australian antibiotics start-up Auspherix

03-12-2013

Auspherix Pty, an early stage anti-infectives company developing novel antibiotics to treat resistant…

Antibiotics and Infectious diseasesAsia-PacificAuspherixAustraliaFinancialPharmaceuticalResearch

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

25-11-2013

Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

UK’s Helperby in deal with Cadila on ARB research and commercialization

14-11-2013

Privately-held Indian drugmaker Cadila Pharmaceuticals and UK based antibiotics discovery company, Helperby…

Antibiotics and Infectious diseasesAsia-PacificCadila PharmaceuticalsHelperby TherapeuticsMarkets & MarketingPharmaceuticalResearch

Venus gets GMP certifications from Ukraine

22-07-2013

Indian R&D-based drugmaker Venus Remedies (BSE: 526953) has been able to gain a Good Manufacturing Practice…

Antibiotics and Infectious diseasesAsia-PacificEuropeMarkets & MarketingOncologyPharmaceuticalProductionRegulationVenus Remedies

India must address worrying stock out of tuberculosis drugs, says MSF

24-06-2013

The Indian government must urgently address the persistent issues and almost routine delays of procuring…

Antibiotics and Infectious diseasesAsia-PacificHealthcareMarkets & MarketingPharmaceuticalPolitics

Cempra out-licenses solithromycin to Toyama Chemical in Japan

15-05-2013

USA-based clinical-stage antibiotics developer Cempra (Nasdaq: CEMP) has signed an exclusive license…

Antibiotics and Infectious diseasesAsia-PacificCempraLicensingPharmaceuticalsolithromycinToyama

BioAlliance Pharma pursues development plan for Loramyc in Japan through partner Sosei

13-03-2013

French orphan oncology and supportive care specialist BioAlliance Pharma (Euronext Paris: BIO) says its…

Antibiotics and Infectious diseasesAsia-PacificBioAlliance PharmaLoramycOravigPharmaceuticalRegulationResearchSosei

MicuRx joins forces with VC for next-generation antibiotic for China

24-10-2012

MicuRx Pharmaceuticals, a privately-held US biopharmaceutical company developing next-generation antibiotics,…

Antibiotics and Infectious diseasesAsia-PacificMergers & AcquisitionsMicuRx PharmaceuticalsMRX-IPharmaceuticalResearchShanghai MengKe Pharma

Pharmaceutical majors unite in Japan to combat H. pylori

18-09-2012

On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Regulatory briefs: Amitiza in Japan; Dificid in Canada; Eurartesim roll-out

06-07-2012

Sucampo Pharmaceuticals (Nasdaq: SCMP) and Abbott Labs (NYSE: ABT) have received approval from the Ministry…

Abbott LaboratoriesAmitizaAntibiotics and Infectious diseasesAsia-PacificDificidEurartesimGastro-intestinalsMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulationSigma-TauSucampoTropical diseases

TaiGen Biotech out-licenses China rights for nemonoxacin, to Zhejiang Medicine

26-06-2012

Taiwan-based TaiGen Biotechnology and China's Zhejiang Medicine Company (SHA: 600216) have signed an…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyZhejiang Medicine

Optimer Pharma could earn $90 million from new Astellas deal

30-03-2012

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

Additional indications in Japan for Diagnogreen and Sawacillin

22-02-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Back to top